乳酸乳球菌载体疫苗

乳酸乳球菌是一种在食品工业中广泛应用的安全级微生物,应用基因工程手段能使乳酸乳球菌表达多种病毒、细菌、寄生虫的外源蛋白。乳酸乳球菌可经粘膜途径免疫,能有效递呈抗原,诱导外源蛋白的特异性免疫应答,并能同时诱导粘膜免疫与全身免疫,因此可作为潜在的疫苗载体。本文对乳酸乳球菌载体疫苗的优势、应用以及疫苗设计时需要考虑的问题进行了概述。     

乳酸乳球菌作为基因工程受体菌研究进展

乳酸乳球菌(Lactococcus lactis)是一种"公认安全"的革兰氏阳性细菌,广泛存在于人、畜的肠道中并发挥许多重要的生理功能。由于它兼具安全性与益生性,近几年来研究者们开始关注用乳酸乳球菌作为受体菌来表达外源蛋白。随着生物技术的发展,人们对乳酸乳球菌基因表达及调控过程的认识不断深入并构建了一系列表达,成功地表达了许多外源蛋白,初步展示出良好的应用前景。主要对近年来国内外将乳酸乳球菌作为外源蛋白表达受体菌方面的研究进展做简要综述。     

鼠疫抗原LcrV在乳酸乳球菌中的表达与鉴定

目的以乳酸乳球菌(Lactococcus lactis)为载体,将鼠疫抗原LcrV基因导入乳酸乳球菌内,构建重组肠道微生态菌株,作为黏膜免疫疫苗的先期探索和尝试。方法采用酸诱导P170启动子,乳酸乳球菌本身的SP310mut2信号肽,将鼠疫杆菌LcrV抗原结构基因克隆到质粒pAM J397上,电转化感受态Lactococcus lactis PSM565。结果经重组子PCR鉴定,SDS-PAGE检测,W estern-b lot鉴定,在Lactococcus lactisPSM565/pAM J397-V培养基上清中获得了38 kD的鼠疫抗原LcrV蛋白。结论在乳酸乳球菌中成功表达了鼠疫V抗原,为下一步鼠疫黏膜疫苗的研制打下基础。     

乳酸乳球菌食品级表达载体的研究进展

乳酸乳球菌（L.lactis）是乳球菌属中最重要和最典型的一个种,在食品工业中应用广泛,被公认为安全的（generally regards as safe,GRAS）食品级微生物。以乳酸乳球菌作为宿主菌,构建表达载体用来表达异源蛋白和酶,逐渐成为食品工业、生物制药和疫苗研究的热点。近年来,乳酸乳球菌的分子微生物学研究取得了重大进展,这为表达载体的构建奠定了基础,一些具有不同用途的乳酸乳球菌基因表达载体已经构建,用来表达抗原蛋白、细胞因子和生物酶等。其中,以来源于食品级微生物的DNA片段构建的食品级表达载体引起人们的关注。     

乳酸乳球菌表面展示技术

乳酸乳球菌(Lactococcus lactis,L.lactis)是革兰氏阳性益生菌,作为食品安全级微生物,它在当今社会的多个方面得到运用。利用基因工程手段可以将多种外源蛋白质表达并展示在乳酸乳球菌的表面,使蛋白质的生物学功能得以展示,进而应用于工业和农业。又由于乳酸乳球菌不产生脂多糖和其他毒素,所以也能很好地运用于医学等相关研究。     

变形链球菌致龋抗原基因在乳酸乳球菌的表达

目的 克隆变形链球菌葡聚糖结合蛋白B(GbpB)功能区的基因片段,并在乳酸乳球菌中表达.方法 在实验中利用了分子克隆技术构建携带GbpB基因的重组原核表达质粒pNI1,将重组质粒转化乳酸乳球菌YF02株,筛选鉴定阳性菌落,诱导表达的GbpB蛋白用SDS-PAGE进行鉴定.结果 成功克隆了GbpB功能区的基因片段,并在乳酸乳球菌中得到其融合蛋白的表达.结论 利用分子生物学技术能够成功克隆GbpB功能区基因并获得乳酸乳球菌融合蛋白的表达,为后续研究奠定了基础.     

乳酸乳球菌基因表达载体系统的研究

乳酸乳球菌（IaCtOCOOCCClaCrts）是乳球菌属（IastOCOCCCS）最重要和最典型的一个种,该菌为兼性厌氧的革兰氏阳性菌,是乳品工业发酵的重要菌类,是在食品及医药工程领域具有重要应用前景的食品级微生物［‘］。乳酸乳球菌中存在大量的染色体外因子（如质粒和噬菌体）,为其分子生物学研究和基因载体系统的发展提供了极好的材料。在近十多年中,随着乳酸乳球菌内源性质粒的去除和电穿孔转基因技术的建立以及乳酸乳球菌各类表达信号的分离和克隆,已建立和发展了一系列具有不同用途的乳酸乳球菌载体和受体系统。这些载体包括基本的…     

基因修饰乳酸乳球菌作为药物发送载体系统治疗黑色素瘤初探

[目的]探讨携带自杀基因单纯疱疹病毒胸苷激酶(HSV-tk)的重组乳球菌静脉注射后靶向实体肿瘤组织定殖及联合更昔洛韦(GCV)治疗小鼠黑色素瘤的可能性。[方法]荷瘤小鼠静脉注射乳球菌3d或7d后,将小鼠脾肺肝肾器官和肿瘤组织细胞匀浆后涂布于筛选培养基上,以乳酸菌数量的评价静脉发送乳球菌靶向定殖肿瘤细胞的可能性。以携带HSVtk的重组乳酸乳球菌经静脉途径处理荷瘤小鼠后,通过观测小鼠肿瘤体积变化及小鼠存活率评价相关抗肿瘤效果。[结果]静脉注射乳酸乳球菌3d后在小鼠脾肺肝肾和肿瘤组织内均有乳球菌检出,而7d后仅在肿瘤组织中发现有乳酸乳球菌的分布。与对照相比,静脉注射LL-HSV-tk联合GCV处理能显著抑制小鼠体内肿瘤的生长。[结论]静脉发送携带治疗性分子的乳酸乳球菌能靶向实体肿瘤组织定殖并抑制肿瘤的生长。     

利用组氨酸合成酶基因作为同源双交换序列构建在乳酸乳球菌中表达炭疽杆菌保护性抗原的载体

目的:为了实现炭疽杆菌保护性抗原(PA)在乳酸乳球菌中的整合性表达,利用组氨酸合成酶基因(HISB)作为同源交换序列构建表达PA的载体。方法:采用PCR等方法将酸启动子P170、红霉素抗性基因、HISB及酶切位点克隆到pMD18-T载体上,命名为pHEC-P170-PA。结果:构建好的双交换载体经酶切电泳鉴定并测序,其序列中含有PA基因。结论:构建了炭疽杆菌保护性抗原基因同源双交换载体。     

乙醛脱氢酶在乳酸乳球菌中的表达与纯化

目的:在乳酸乳球菌中重组表达乙醛脱氢酶(ALDH).方法:合成毕赤酵母ALDH基因,PCR扩增后通过重组构建pNZ8048-ALDH表达载体,电转至乳酸乳球菌NZ9000感受态,Nisin诱导表达后经Ni柱亲和层析纯化ALDH蛋白,比色法测定酶活.结果:构建了pNZ8048-ALDH表达载体,在乳酸乳球菌NZ9000中...     

Oral administration of Lactococcus lactis expressing Helicobacter pylori Cag7-ct383 protein induces systemic anti-Cag7 immune response in mice

To express the 3'-region (1152 bp) of the cag7 gene of Helicobacter pylori 51 strain, encoding the C-terminal 383 amino acid (ct383 aa) region of Cag7 protein that is known to cover the needle region of T4SS, in a live delivery vehicle Lactococcus lactis , the cag7-ct383 gene was amplified by PCR. DNA sequence analysis revealed that the amino acid sequence of Cag7-ct383 of H. pylori 51 shared 98.4% and 97.4% identity with H. pylori 26695 and J99, respectively. Intramuscular injection of the GST-Cag7-ct383 fusion protein into a rat could raise the anti-Cag7 antibody, indicating the immunogenicity of the Cag7-ct383 protein. When the cag7-ct383 gene was cloned in Escherichia coli–L. lactis shuttle vector (pMG36e) and transformed into L. lactis , the transformant could produce the Cag7-ct383 protein, as evidenced by Western blot analysis. The Cag7-ct383 protein level in the L. lactis transformant reached a maximum at the early stationary phase without extracellular secretion. The oral administration of the L. lactis transformant into mice generated anti-Cag7 antibody in serum in five of five mice. These results suggest that L. lactis transformant expressing Cag7-ct383 protein may be applicable as an oral vaccine to induce mucosal and systemic immunity to H. pylori .     

Oral vaccination of mice against Helicobacter pylori with recombinant Lactococcus lactis expressing urease subunit B

To determine whether a protective immune response could be elicited by oral delivery of a recombinant live bacterial vaccine, Helicobacter pylori urease subunit B (UreB) was expressed for extracellular expression in food-grade bacterium Lactococcus lactis . The UreB-producing strains were then administered orally to mice, and the immune response to UreB was examined. Orally vaccinated mice produced a significant UreB-specific serum immunoglobulin G (IgG) response. Specific anti-UreB IgA responses could be detected in the feces of mice immunized with the secreting lactococcal strain. Mice vaccinated orally were significantly protected against gastric Helicobacter infection following a challenge with H. pylori strain SS1. In conclusion, mucosal vaccination with L. lactis expressing UreB produced serum IgG and UreB-specific fecal IgA, and prevented gastric infection with H. pylori .     

Protective immunity of SpaA-antigen producing Lactococcus lactis against Erysipelothrix rhusiopathiae infection

AIMS: To develop an economical, safe and simple vaccination system against swine erysipelas using SpaA-antigen producing Lactococcus lactis. METHODS AND RESULTS: The spaA gene of Erysipelothrix rhusiopathiae was inserted into a shuttle plasmid pSECE1 to construct pSECE1.3. The SpaA produced in L. lactis maintained a stable antigenicity without degrading in growth. After mice were inoculated intranasally and orally with pSECE1.3-carrying L. lactis cells, IgG and IgA specific to SpaA were detected, and all the mice survived a challenge with 100 LD(50) of E. rhusiopathiae Tama-96 in the inner thigh. CONCLUSIONS: SpaA-producing L. lactis appears useful as an effective subunit vaccine against swine erysipelas. SIGNIFICANCE AND IMPACT OF THE STUDY: In this vaccination system, purification of the antigen and injection are unnecessary, leading to a reduced production cost, reduced labour and less stress to the animals. This vaccination system of the lactic acid bacteria should be a safe and suitable vehicle for a polyvalent vaccine.     

α-Galactosidase from Alfalfa Seeds (Medicago sativa L.)

An α-galactosidase from alfalfa seeds was purified 140-fold by ammonium sulfate fractionation, and column chromatography on Sephadex G-100, DEAE- and CM-Sephadex. Polyacrylamide-gel electrophoresis of the purified enzyme showed a single protein band. The molecular weight was estimated to be approximately 57,000 by gel-filtration. The purified enzyme hydrolyzed p-nitrophenyl α-d-galactoside more rapidly than raffinose. The maximal enzyme activities were obtained at pH 4.0 and 5.5 for p-nitrophenyl α-d-galactoside and at 4.5 for raffinose. The enzyme was shown to be inhibited by Hg²⁺ and Ag⁺ ions, and d-galactose.     

产抑菌素菌株SM—A的分离和鉴定

自市售酸乳酪中分离到一株乳球菌SM-A菌株。该菌株产生的抑菌素能抑制或杀死芽孢杆菌、葡萄球菌、微球菌、链球菌、棒杆菌和梭菌等革兰氏阳性细菌,但对革兰氏阴性细菌、霉菌和酵母无效。SM-A菌株多为链球状,也有成对存在。革兰氏染色阳性,抗酸染色阴性,兼性厌氧生长,最适生长温度32℃,不形成芽孢,无荚膜和鞭毛,不运动;可从多种糖类产酸,但不产气;接触酶、苯丙氨酸脱氨酶和酪氨酸脱羧酶均为阴性,精氨酸双水解酶阳性;不液化明胶,还原石蕊牛奶并胨化,生长温度范围10～43℃,DNA中G Cmol为36.4％。经鉴定,SM-A菌株为乳酸乳球菌乳酸亚种(Lactococcus lactis subsp.lactis)。     

Gene expression in Lactococcus lactis

Abstract Lactic acid bacteria are of major economic importance, as they occupy a key position in the manufacture of fermented foods. A considerable body of research is currently being devoted to the development of lactic acid bacterial strains with improved characteristics, that may be used to make fermentations pass of more efficiently, or to make new applications possible. Therefore, and because the lactococci are designated 'GRAS' organisms ('generally recognized as safe') which may be used for safe production of foreign proteins, detailed knowledge of homologous and heterologous gene expression in these organisms is desired. An overview is given of our current knowledge concerning gene expression in Lactococcus lactis . A general picture of gene expression signals in L. lactis emerges that shows considerable similarity to those observed in Escherichia coli and Bacillus subtilis . This feature allowed the expression of a number of L. lactis -derived genes in the latter bacterial species. Several studies have indicated, however, that in spite of the similarities, the expression signals from E. coli, B. subtilis and L. lactis are not equally efficient in these three organisms.     

Live recombinant Lactococcus lactis vaccine expressing aerolysin genes D1 and D4 for protection against Aeromonas hydrophila in tilapia (Oreochromis niloticus)

Aims: To evaluate a live recombinant Lactococcus lactis vaccine expressing aerolysin genes D1 (Lac‐D1ae) and/or D4 (Lac‐D4ae) in protection against Aeromonas hydrophila in tilapia (Oreochromis niloticus). Methods and Results: The polymerase chain reaction (PCR)‐amplified 250‐ and 750‐bp sequences coding for domains D1 and D4 of aerolysin were individually cloned into pNZ8048 and electrotransformed into L. lactis. The recombinant vaccine candidates were then either orally fed or injected intraperitoneally into tilapia. The development of antibodies in sampled fish compared to control groups implied that the recombinant epitopes expressed in L. lactis were able to elicit an immunogenic response in tilapia. Interestingly, the lower doses of both Lac‐D1ae and Lac‐D4ae gave higher antibody levels over the study period. Fish immunized with Lac‐D1ae and Lac‐D4ae together showed the highest level of protection, and the mortality was reduced significantly compared to control strains in both modes of vaccination. Conclusions: The recombinant L. lactis strain expressing D1 and D4 produced aerolysin‐specific serum IgM in tilapia. Both D1 and D4 promoted 55–82% relative per cent survival (RPS) against Aeromonas infection through intraperitoneal injection, whereas the RPS following oral feeding of the vaccine was 70–100%. Significance and Impact of the Study: The D1 and D4 regions of the aerolysin protein have been successfully identified as immunogenic regions that can elicit antibody production in tilapia and protect against challenge with Aer. hydrophila. A promising oral vaccine using L. lactis harbouring the D1 and D4 regions has been developed to control Aer. hydrophila.